ESMO 2022 on the Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study: Adagrasib in KRASG12Cm NSCLC | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

ESMO 2022 Conference Coverage

ESMO 2022 on the Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study: Adagrasib in KRASG12Cm NSCLC

By ESMO 2022 Conference Coverage FEATURING Jun Zhang

By ESMO 2022 Conference Coverage FEATURING Jun Zhang

273 views

September 27, 2022

This video was recorded prior to the FDA granting approval to Adagrasib (Krazati) on December ...
read more ↘

Comments 0

Login to view comments. Click here to Login